<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Uremic myopathy and deconditioning in patients with chronic kidney disease (including those on dialysis)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Uremic myopathy and deconditioning in patients with chronic kidney disease (including those on dialysis)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Uremic myopathy and deconditioning in patients with chronic kidney disease (including those on dialysis)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Brent W Miller, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel C Brennan, MD, FACP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gary C Curhan, MD, ScD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eric N Taylor, MD, MSc, FASN
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 13, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with advanced chronic kidney disease (CKD), particularly those on dialysis, often have significant muscle weakness and lack of endurance. This often results in a sedentary lifestyle that causes progressive deconditioning and increases morbidity and mortality among patients on dialysis. Exercise may reverse or mitigate effects of deconditioning and improve survival.
        </p>
        <p>
         This topic reviews the pathophysiology of uremic myopathy and its effect on sedentary lifestyle among patients with CKD, including those on dialysis. The beneficial effects of exercise are discussed and recommendations provided for patients with nondialysis CKD and those on dialysis.
        </p>
        <p>
         The effects of a sedentary lifestyle and the effects of exercise in the general adult population are discussed elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2786.html" rel="external">
          "The benefits and risks of aerobic exercise"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16524.html" rel="external">
          "Physical activity and exercise in older adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5379.html" rel="external">
          "Obesity in adults: Role of physical activity and exercise"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3357592163">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Uremic myopathy is considered common in patients with advanced CKD, particularly those on dialysis given the obvious decline in physical function observed [
         <a href="#rid1">
          1,2
         </a>
         ]. However, the prevalence of a specific pathophysiological process directly attributable to uremia is not well defined, since the symptoms are minor and slowly evolving coupled with the lack of specific diagnostic criteria [
         <a href="#rid3">
          3
         </a>
         ]. In one study including 330 patients on dialysis, sarcopenia (defined as decreased muscle mass with decreased function/mobility) was present in 20 percent, decreased muscle mass alone was present in 24 percent, and decreased muscle strength was present in 15 percent [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H936245490">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Factors that cause sarcopenia or atrophy and weakness among patients with CKD include uremia-induced inflammation and accumulation of reactive oxygen species resulting in mitochondrial uncoupling and deficient muscle repair mechanisms [
         <a href="#rid5">
          5-7
         </a>
         ]. Deconditioning not specific to CKD also plays an important role in progressive muscle impairment as do comorbid illnesses such as diabetes mellitus, poor nutrition, and peripheral vascular disease. Erythropoietin, vitamin D, and androgen deficiencies all likely contribute to muscle weakness.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mitochondrial uncoupling
         </strong>
         – Studies have suggested that there is a decrease in mitochondrial efficiency in CKD that is characterized by a decline in adenosine triphosphate (ATP) production per unit of oxygen consumption (ie, mitochondrial uncoupling) [
         <a href="#rid8">
          8,9
         </a>
         ]. Mitochondrial uncoupling may occur prior to the functional decline in exercise tolerance and endurance [
         <a href="#rid10">
          10
         </a>
         ]. The initial cause of mitochondrial uncoupling is not known but may be related to increased oxidative stress as the glomerular filtration rate (GFR) declines [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Deconditioning
         </strong>
         – Deconditioning is a major contributor to the progressive myopathy among patients with CKD. Deconditioning is a loss of muscle mass (sarcopenia), strength, and power that occurs as a result of inactivity [
         <a href="#rid12">
          12
         </a>
         ]. The role of deconditioning in uremic myopathy was demonstrated in a study that used resting muscle oxygen consumption (rmVO2) as a marker of myopathy [
         <a href="#rid13">
          13
         </a>
         ]. The rmVO2 was twice as high in patients with end-stage kidney disease (ESKD) compared with healthy controls.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with CKD are extremely vulnerable to deconditioning. Patients with CKD tend to be less active than sedentary healthy controls [
         <a href="#rid14">
          14-16
         </a>
         ]. The reasons for the decreased activity level are not completely understood, but early muscle fatigue (possibly caused by mitochondrial uncoupling), orthostatic hypotension, anemia, and multiple comorbidities and hospitalizations may play a role.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Deconditioning is reversible. In the study cited above, six months of exercise caused a decrease in the rmVO2 of patients with ESKD; 39 percent achieved a normal rmVO2 [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Multiple studies have shown that exercise improves the muscular functioning and physical performance of patients with CKD [
         <a href="#rid17">
          17-19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Erythropoietin deficiency
         </strong>
         – Erythropoietin deficiency may contribute to myopathy, but it is not clear whether this is because the resulting anemia causes a decrease in oxygen delivery to muscle and/or contributes to inactivity and deconditioning or whether erythropoietin has direct effects on muscle.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The correction of anemia with erythropoietin improves endurance and strength in patients with CKD [
         <a href="#rid20">
          20
         </a>
         ]. In an early study, the correction of anemia with erythropoietin to a target hemoglobin of 11 g/dL in 11 previously transfusion-dependent patients on dialysis resulted in a 10 to 30 percent increase in arm and leg muscle strength in three months, although this improvement still left the patients significantly less strong than healthy controls [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Muscle structure improves with erythropoietin treatment. In one study, muscle biopsies performed before and after correction of anemia showed an improvement in the diameter of muscle fibers and a reduction in structural abnormalities after partial correction of anemia [
         <a href="#rid22">
          22
         </a>
         ]. These changes would be expected to produce an increase in both muscle strength and performance and are most probably a consequence of an increase in muscle oxygen delivery. (See
         <a class="medical medical_review" href="/z/d/html/1952.html" rel="external">
          "Treatment of anemia in nondialysis chronic kidney disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1935.html" rel="external">
          "Hyporesponse to erythropoiesis-stimulating agents (ESAs) in chronic kidney disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         That erythropoietin may have a direct effect on muscle (ie, that is unrelated to anemia) is suggested by the fact that the correction of anemia with transfusion in nonuremic patients (who would not be expected to have a decrease in endogenous erythropoietin levels) does not appear to improve muscle function [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Androgen deficiency
         </strong>
         – Both male and female patients with CKD have decreased androgen production. (See
         <a class="medical medical_review" href="/z/d/html/7459.html" rel="external">
          "Causes of primary hypogonadism in males", section on 'Chronic kidney disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Androgen deficiency likely contributes to muscle impairment. Prior to the availability of recombinant erythropoietin, androgen therapy was used to treat anemia in some patients on hemodialysis [
         <a href="#rid24">
          24,25
         </a>
         ], and, in one study, the androgen, nandrolone decanoate, was noted to increase muscle mass [
         <a href="#rid25">
          25,26
         </a>
         ]. This agent was subsequently shown to improve body composition and muscle strength [
         <a href="#rid27">
          27,28
         </a>
         ]. In one study, 79 patients were randomly assigned in a 2x2 factorial fashion to anabolic steroid administration and resistance exercise training [
         <a href="#rid28">
          28
         </a>
         ]. Nandrolone administration increased lean body mass and quadriceps muscle size, while exercise increased muscle size alone.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vitamin D deficiency
         </strong>
         – Vitamin D deficiency has been associated with myopathies of various causes including statin-induced and vitamin D-dependent rickets [
         <a href="#rid29">
          29-31
         </a>
         ]. In several reports, supplementation with appropriate doses of vitamin D improved muscle function [
         <a href="#rid29">
          29-31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5804.html" rel="external">
          "Etiology and treatment of calcipenic rickets in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14590.html" rel="external">
          "Vitamin D insufficiency and deficiency in children and adolescents", section on 'Skeletal changes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Secondary hyperparathyroidism
         </strong>
         – Myopathy has been reported in patients with both primary [
         <a href="#rid32">
          32-35
         </a>
         ] and secondary hyperparathyroidism [
         <a href="#rid36">
          36,37
         </a>
         ]. The myopathy associated with primary hyperparathyroidism has been shown to be reversible with reduction in parathyroid hormone (PTH) suggesting causality [
         <a href="#rid33">
          33,35
         </a>
         ]. However, it is difficult to distinguish effects of PTH from those of vitamin D deficiency and uremia in published reports of secondary hyperparathyroidism [
         <a href="#rid36">
          36,37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Carnitine deficiency
         </strong>
         – Some studies demonstrated that L-carnitine supplementation improved muscle strength but not endurance [
         <a href="#rid38">
          38,39
         </a>
         ]. However, when muscle metabolism and function were assessed by magnetic resonance or near-infrared spectroscopy, L-carnitine supplementation for 16 weeks in patients receiving maintenance hemodialysis showed no effect [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dialysis access
         </strong>
         – The hemodialysis access may have local effects on muscle function. A forearm access likely affects the function of both large and fine motor skills in the affected arm [
         <a href="#rid41">
          41
         </a>
         ]. A hemodialysis access or peritoneal dialysis catheter may also decrease patient activity for fear of harming the access or catheter. Although restrictions are often placed upon patients with various access (eg, swimming and heavy lifting with peritoneal catheters; lifting with the vascular access arm, heavy perspiration, or swimming with a hemodialysis catheter; etc), these recommendations are largely based on anecdotal practices.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other factors
         </strong>
         – Other factors that may contribute in some patients include steroid myopathy, altered potassium metabolism, and malnutrition. These factors are generally recognized to be associated with decreased muscle function. (See
         <a class="medical medical_review" href="/z/d/html/5171.html" rel="external">
          "Glucocorticoid-induced myopathy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2847041637">
         <span class="h1">
          CLINICAL PRESENTATION AND DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Uremic myopathy is defined by a constellation of signs and symptoms including muscle weakness and wasting involving both proximal and distal muscles, decreased endurance and exercise capacity, and easy fatigability [
         <a href="#rid3">
          3,42
         </a>
         ]. The severity increases as the glomerular filtration rate (GFR) declines [
         <a href="#rid43">
          43
         </a>
         ]; the most severe cases have been described among patients on hemodialysis [
         <a href="#rid3">
          3,44
         </a>
         ].
        </p>
        <p>
         Except for weakness, the physical examination is normal. Electromyographic studies and muscle enzymes are also normal [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Atrophy may be observed by imaging [
         <a href="#rid44">
          44,45
         </a>
         ]. In one study, magnetic resonance imaging (MRI) of the lower extremities showed less contractile tissue among patients on dialysis compared with controls, although the total cross-sectional area was comparable [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
         Muscle biopsies show characteristic structural, electrolyte, and enzymatic abnormalities [
         <a href="#rid3">
          3,46-48
         </a>
         ]. In a small study in which muscle biopsies from eight patients with CKD were compared with healthy controls, light microscopy showed atrophy, particularly involving type 2 muscle fibers (ie, "fast twitch" or anaerobic) and evidence of degeneration and regeneration of muscle fibers [
         <a href="#rid46">
          46
         </a>
         ]. Electron microscopy showed mitochondrial changes, loss of myofilaments, and the accumulation of intracellular glycogen. However, it is not clear how closely the structural muscle abnormalities correlate with functional impairment [
         <a href="#rid1">
          1,2,49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4186299389">
         <span class="h1">
          SCREENING
         </span>
         <span class="headingEndMark">
          —
         </span>
         We screen most patients on hemodialysis, and selected patients with CKD not on hemodialysis whose symptoms appear out of proportion to their comorbid illness, for functional limitations. Screening for physical performance and self-reported functional limitation (defined by restrictions in basic activities such as ambulation and climbing stairs) may identify patients at risk for further functional decline, disability, and increased mortality [
         <a href="#rid4">
          4,5
         </a>
         ].
        </p>
        <p>
         The following screening questions have been proposed to assess functional and mobility limitations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Do you have difficulty walking a quarter of a mile (two to three city blocks) or climbing 10 steps?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Have you changed the way you walk a quarter of a mile or how often you do this because of a physical condition?
        </p>
        <p>
        </p>
        <p>
         In addition, physical performance may be objectively quantitated. There are multiple tests of physical function that are simple to administer and are commonly used in the non-CKD population, including the six-minute walk test, intermittent shuttle walk test, gait speed, and timed up and go test [
         <a href="#rid50">
          50
         </a>
         ]. We use tests of gait speed or a timed up and go test. For measure of gait speed, the patient walks at their usual speed over 3 meters and is allowed to stop and rest as necessary. Walking speed &lt;0.8 m/s has been associated with increased mortality in patients with CKD [
         <a href="#rid51">
          51
         </a>
         ]. For the timed up and go test, the patient must stand from a fully seated position and walk 4 meters; time ≥4 seconds is associated with increased mortality in CKD.
        </p>
        <p>
         Many transplant centers are now using objective measurements of physical function as screening criteria for suitability for kidney transplantation. As an example, our center sets 1000 feet in a six-minute walk as a minimum standard.
        </p>
        <p>
         Other tests are being developed to assess for a variety of functional limitations in patients with kidney disease. As an example, a pilot study of patients with CKD identified smaller step length and slower gait speed as risk factors for falls [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3833857991">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is possible that myopathy cannot be prevented completely, particularly those aspects that are directly related to uremia (ie, oxidative injury and mitochondrial uncoupling). However, the prevention or treatment of deconditioning may delay or mitigate the progression of clinically significant muscle impairment [
         <a href="#rid53">
          53
         </a>
         ]. Our approach for all patients includes an exercise regimen plus optimal treatment of vitamin D deficiency, anemia, and nutrition and is defined below.
        </p>
        <p>
         Selected patients will have persistent and debilitating myopathy and atrophy despite these measures. Such patients may benefit from referral to a physical therapist or exercise physiologist as well as pharmacologic therapies. (See
         <a class="local">
          'Treatment'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3431300993">
         <span class="h2">
          Active lifestyle and exercise
         </span>
         <span class="headingEndMark">
          —
         </span>
         We counsel all patients with CKD, including those on dialysis, to maintain an active lifestyle. Physical activity confers multiple benefits including prevention of progression of muscle impairment [
         <a href="#rid53">
          53
         </a>
         ]. (See
         <a class="local">
          'Benefits of exercise'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2869478921">
         <span class="h3">
          Patients with CKD not on dialysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with CKD should follow recommendations for aerobic exercise, muscle strengthening, flexibility, and balance that exist for the general population (see
         <a class="medical medical_review" href="/z/d/html/16524.html" rel="external">
          "Physical activity and exercise in older adults", section on 'Overview of physical activity components'
         </a>
         ). A reasonable goal for patients with CKD is 150 minutes per week of moderate aerobic activity or 75 minutes per week of vigorous aerobic physical activity, with additional resistance training as appropriate [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2807576505">
         <span class="h3">
          Patients on dialysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         At our center, all patients undergoing dialysis are encouraged to participate in an exercise program after appropriate screening for medical limitations. The amount of exercise depends upon patient capability. For those who are capable, we advise patients to follow recommendations for the general public. A reasonable exercise dose would be walking a minimum of 4000 steps daily [
         <a href="#rid55">
          55
         </a>
         ], and this approach has shown positive effects in a randomized trial, even with older patients [
         <a href="#rid19">
          19,56
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16524.html" rel="external">
          "Physical activity and exercise in older adults", section on 'Overview of physical activity components'
         </a>
         .)
        </p>
        <p>
         However, patients on dialysis are frequently deconditioned and frail. Although functionally limited or frail individuals may never be able to meet minimum recommended activity levels, even modest activity and muscle strengthening can impact the progression of functional limitations [
         <a href="#rid57">
          57,58
         </a>
         ]. While all elements of the physical activity recommendations should be incorporated into an activity plan, the adage "start low and go slow" should be kept in mind. It is acceptable to begin a baseline physical activity recommendation of walking for five minutes twice a day as a starting point. The key is to identify a set of activities the patient feels capable of doing, therefore incorporating the concept of self-efficacy into the physical activity recommendation [
         <a href="#rid59">
          59
         </a>
         ]. Some dialysis centers, including ours, have offered basic stationary cycling at the dialysis center in the treatment chair during dialysis. Improvement occurs within 12 weeks of this simple program, although only approximately 20 percent of patients participate regularly [
         <a href="#rid60">
          60
         </a>
         ]. Historically, some clinicians have been reluctant to permit exercise during the latter portions of the dialysis session due to a concern that physical activity near the end of dialysis might precipitate intradialytic hypotension. However, this concern is unfounded for most patients. In a crossover trial in which 98 patients on hemodialysis were randomly assigned to two sequential two-week intradialytic cycling regimens that occurred either during the first or second half of the dialysis session, the timing of intradialytic cycling had no appreciable effect on the rate or severity of intradialytic hypotension [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
         Patients on peritoneal dialysis have the same low physical performance measures as patients on hemodialysis [
         <a href="#rid62">
          62
         </a>
         ]. For patients on peritoneal dialysis, a stretching and walking program is recommended at home, with observance of guidelines suggested to the general public [
         <a href="#rid63">
          63
         </a>
         ]. Occasionally, patients will state that the presence of dialysis fluid limits their activity. For these patients, we drain the abdomen for one to two hours during their period of physical activity. Some patients may have concerns that exercise can lead to peritoneal dialysis catheter problems (eg, exit-site infections, leaks, pulling trauma) or the development of abdominal hernias that complicate the peritoneal dialysis regimen. However, none of these issues were observed in a systematic review that included 17 exercise or physical intervention studies of patients on peritoneal dialysis [
         <a href="#rid64">
          64
         </a>
         ]. Further discussion of exercise among frail or functionally limited patients is elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/16524.html" rel="external">
          "Physical activity and exercise in older adults", section on 'Functionally limited or frail'
         </a>
         .)
        </p>
        <p>
         Physical therapy has not been routinely incorporated into the care of patients with end-stage kidney disease (ESKD). Although one assumes a potential benefit, no large trial has examined the utility or benefit of routine referral to a physical therapist or exercise physiologist following the diagnosis of ESKD.
        </p>
        <p class="headingAnchor" id="H3605897110">
         <span class="h3">
          Benefits of exercise
         </span>
        </p>
        <p class="headingAnchor" id="H1520736066">
         <span class="h4">
          Prevention of atrophy and myopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of studies have shown that exercise helps to preserve or improves muscle function and/or mass among patients with nondialysis and dialysis CKD, including those on a low-protein diet [
         <a href="#rid17">
          17,18,65-76
         </a>
         ]. The best data are from two meta-analyses of randomized trials that showed improvements in muscle strength with exercise [
         <a href="#rid17">
          17,18
         </a>
         ]. Regardless of type, intensity, or length of intervention, exercise improved muscle strength at all stages of CKD [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         In a trial published after the meta-analyses, 296 patients on dialysis were randomly assigned to six months of a walking exercise program or usual physical activity [
         <a href="#rid19">
          19
         </a>
         ]. At six months, patients in the exercise group experienced improvements in measured physical performance compared with baseline (as determined by six-minute walking test distance and five-times sit-to-stand test time), whereas those in the usual activity group did not. In addition, patients in the walking exercise group, compared with those in the usual physical activity group, had lower rates of hospitalization (35 versus 57 hospitalizations per 100 person-years, respectively) and improved cognitive and social interaction scores on the Kidney Disease Quality of Life Short Form (KDQOL-SF) questionnaire. A subsequent observational study of these trial participants found that those in the exercise group had a superior performance in the six-minute walking test, but not in the sit-to-stand test or in the KDQOL-SF score, compared with the control group up to 12 months after the end of the exercise intervention [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H448748242">
         <span class="h4">
          Slowing of decline in GFR
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple studies have suggested that exercise slows the decline in kidney function and reduces the risk of requiring dialysis [
         <a href="#rid78">
          78-80
         </a>
         ]. The best data are from a randomized, controlled trial that compared the effects of a three-times-weekly exercise regimen (including both resistance and aerobic training) to usual care among 20 patients (17 men) who had a rate of decline in estimated glomerular filtration rate (eGFR) of 2.9 mL/min/1.73 m
         <sup>
          2
         </sup>
         per year for 12 months prior to intervention [
         <a href="#rid78">
          78
         </a>
         ]. In the group undergoing exercise, the mean change in eGFR was -9.7±7.2 mL/min/1.73 m
         <sup>
          2
         </sup>
         during the year prior to intervention and -3.8±2.8 mL/min/1.73 m
         <sup>
          2
         </sup>
         per year in the year during which they performed exercise. At 12 months, compared with the control group, the mean rate of change in eGFR was lower in the exercise group, with a mean difference between groups of 7.8±3.0 mL/min/1.73 m
         <sup>
          2
         </sup>
         (95% CI, 1.1-13.5). There was no difference between groups in the absolute eGFRs at 12 months.
        </p>
        <p>
         Longer-term data are limited to observational studies. A longitudinal cohort study compared physical activity, quantitated using the Four-Week Physical Activity History Questionnaire, with longitudinal measurement of eGFR at a median follow-up of 3.7 years [
         <a href="#rid79">
          79
         </a>
         ]. Individuals who reported over 150 minutes of physical activity per week had a slower decline in eGFR compared with inactive individuals (-6.2 versus -9.6 percent per year, respectively). At a median follow-up of 3.7 years, each 60-minute increment in weekly activity was associated with a 0.5 percent slower decline in kidney function in adjusted analysis.
        </p>
        <p class="headingAnchor" id="H2475087655">
         <span class="h4">
          Cardiovascular benefit
         </span>
         <span class="headingEndMark">
          —
         </span>
         The ill effects of sedentary lifestyle on cardiovascular disease and mortality are well accepted, and a benefit of exercise has been suggested by observational studies [
         <a href="#rid81">
          81
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1510.html" rel="external">
          "Exercise and fitness in the prevention of atherosclerotic cardiovascular disease", section on 'Benefits of exercise'
         </a>
         .)
        </p>
        <p>
         A few studies have examined the association between survival and exercise in patients on dialysis [
         <a href="#rid80">
          80,82,83
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an analysis of observational data for 2507 patients from the USRDS Dialysis Morbidity and Mortality Study (Wave 2), decreased mortality was associated in patients who exercised two to three and four to five times per week [
         <a href="#rid82">
          82
         </a>
         ]. However, for unclear reasons, daily exercise provided no survival benefit.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one study of 6363 patients from China, walking was associated with decreased mortality in patients with CKD not on dialysis [
         <a href="#rid80">
          80
         </a>
         ]. Compared with those who reported not walking at all (frequency = 0), the adjusted hazard ratios (HRs) were 0.83, 0.72, 0.42, and 0.41 for patients who walked one to two, three to four, five to six, and seven or more times per week, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an analysis of data from the Dialysis Outcomes and Practice Patterns Study (DOPPS), in which 5763 participants were classified into increasing levels of physical activity, aerobic activity was associated with decreased mortality [
         <a href="#rid83">
          83
         </a>
         ]. The adjusted HR for death for very active participants compared with never or rarely active participants was 0.60 (95% CI 0.47-0.77).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Aerobic activity was also associated with increased health-related quality of life and decreased depression in this study.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a small trial in which 74 patients on hemodialysis were randomly assigned to 60 minutes of intradialytic exercise thrice weekly for six months or to usual care, one-year survival was higher in the exercise group [
         <a href="#rid84">
          84
         </a>
         ]. However, participants in the exercise group were younger and were less likely to have diabetes than participants in the control group.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3102746173">
         <span class="h4">
          Other benefits
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other benefits of exercise include improved aerobic capacity and cardiovascular function [
         <a href="#rid17">
          17,85
         </a>
         ], a reduction in severity of restless leg syndrome and improvement in sleep quality [
         <a href="#rid86">
          86
         </a>
         ], improved quality of life in general [
         <a href="#rid85">
          85
         </a>
         ], and improved social interactions as assessed by the KDQOL-SF questionnaire [
         <a href="#rid18">
          18,19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1667815054">
         <span class="h2">
          Treatment of vitamin D deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         We measure 25-hydroxyvitamin D and treat vitamin D deficiency according to standards set for the general population. The restoration of vitamin D levels has been shown to reduce muscle weakness in case reports [
         <a href="#rid29">
          29-31
         </a>
         ]. (See
         <a class="local">
          'Pathophysiology'
         </a>
         above.)
        </p>
        <p>
         However, a randomized controlled trial did not show a beneficial effect of
         <a class="drug drug_general" data-topicid="10117" href="/z/d/drug information/10117.html" rel="external">
          cholecalciferol
         </a>
         on muscle strength and functional capacity among patients on hemodialysis [
         <a href="#rid87">
          87
         </a>
         ]. Sixty individuals were randomly assigned to receive either oral cholecalciferol, 50,000 international units, or placebo weekly for eight weeks and then monthly for four months. At six months, there was no difference between groups in muscle strength, functional capacity, or health-related quality of life, despite higher values of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D.
        </p>
        <p>
         We do not treat secondary hyperparathyroidism specifically to improve muscle weakness. The treatment of secondary hyperparathyroidism is discussed elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1964.html" rel="external">
          "Management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1918.html" rel="external">
          "Management of secondary hyperparathyroidism in adult patients on dialysis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">
          "Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment", section on 'Vitamin D replacement'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1710768037">
         <span class="h2">
          Treatment of anemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         We carefully monitor for the development of iron deficiency and anemia and treat to accepted thresholds for patients with CKD. (See
         <a class="medical medical_review" href="/z/d/html/1952.html" rel="external">
          "Treatment of anemia in nondialysis chronic kidney disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1926.html" rel="external">
          "Treatment of anemia in patients on dialysis"
         </a>
         .)
        </p>
        <p>
         Erythropoiesis-stimulating agents (ESAs) are generally not given until the hemoglobin is &lt;10 g/dL for patients with CKD not on dialysis. However, we are attentive to possible symptoms of anemia in younger patients who have CKD with few comorbidities, whose symptoms of anemia may occur at higher hemoglobin levels (particularly if the patient is trying to maintain the recommended active lifestyle). For such patients, we may initiate ESAs at hemoglobin levels of 10 g/dL or even higher after discussing potential risks and benefits with each patient. (See
         <a class="medical medical_review" href="/z/d/html/1952.html" rel="external">
          "Treatment of anemia in nondialysis chronic kidney disease", section on 'Indications and contraindications'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H994073725">
         <span class="h2">
          Dietary protein intake
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients placed on a low-protein diet are particularly prone to loss of muscle mass. We generally recommend the same intake of high-quality protein for patients with CKD as is generally recommended for the general population (ie, 0.8 g/kg/day). If patients have a lower protein intake than this, they should be followed closely by a kidney dietitian to be certain that nutrition is adequate since malnutrition almost certainly contributes to muscle weakness. (See
         <a class="medical medical_review" href="/z/d/html/7178.html" rel="external">
          "Dietary recommendations for patients with nondialysis chronic kidney disease", section on 'Protein intake'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3357907434">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite the preventive therapies defined above, some patients will have persistent and debilitating weakness (generally identified by screening as defined above); such patients should be referred to a physical therapist or an exercise physiologist. Although there is no high-quality evidence to support their routine use, pharmacologic treatment options include
         <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">
          testosterone
         </a>
         and
         <a class="drug drug_general" data-topicid="10109" href="/z/d/drug information/10109.html" rel="external">
          carnitine supplementation
         </a>
         :
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In all male patients with persistent and debilitating weakness and no contraindication to androgen therapy, we evaluate for
         <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">
          testosterone
         </a>
         deficiency and, if present, we treat with testosterone replacement therapy for three months and reassess muscle strength. If the patient demonstrates an improvement in muscle strength, we continue testosterone therapy indefinitely. If the patient demonstrates no improvement in muscle strength, we discontinue testosterone therapy. Details on the diagnosis and treatment of testosterone deficiency are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/7462.html" rel="external">
          "Clinical features and diagnosis of male hypogonadism"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7461.html" rel="external">
          "Testosterone treatment of male hypogonadism"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In male patients on hemodialysis who do not have
         <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">
          testosterone
         </a>
         deficiency or who do not respond to testosterone replacement therapy, a three- to six-month trial of intravenous (IV) L-carnitine supplementation (1000 mg at hemodialysis three times weekly) can be considered. However, the use of IV L-carnitine in patients on hemodialysis remains controversial [
         <a href="#rid88">
          88,89
         </a>
         ]. The biochemical diagnosis of carnitine deficiency is difficult since nearly all patients on dialysis have abnormalities in serum carnitine levels, and no study has demonstrated a correlation between various blood carnitine measurements and muscle function.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In female patients with persistent and debilitating weakness, we do not routinely evaluate for
         <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">
          testosterone
         </a>
         deficiency, since the role of androgen therapy in women is limited to the treatment of postmenopausal women with a diagnosis of female sexual interest/arousal disorder. In patients on hemodialysis, a three- to six-month trial of IV L-carnitine can be considered as discussed above for male patients. (See
         <a class="medical medical_review" href="/z/d/html/7447.html" rel="external">
          "Overview of androgen deficiency and therapy in females"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We do not give growth hormone. Although the anabolic effects of
         <a class="drug drug_general" data-topicid="9456" href="/z/d/drug information/9456.html" rel="external">
          recombinant human growth hormone
         </a>
         (rhGH) have been reported in many muscle-wasting conditions, including CKD [
         <a href="#rid88">
          88
         </a>
         ], there are little data that show a sustained improvement in physical function and strength with rhGH administration. One placebo-controlled study of 20 patients reported increased handgrip strength and anabolic effects with subcutaneous rhGH at 66.7 mcg/kg thrice weekly following hemodialysis [
         <a href="#rid89">
          89
         </a>
         ]. A phase III, international, multicenter trial of over 2000 patients on hemodialysis was terminated early due to slow recruitment but showed no improvement in grip strength or walking capacity in the 695 patients who received at least one dose of study medication [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3052330424">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Decreased muscle strength is associated with increased mortality. This was best shown in an observational study including 330 patients on dialysis, 29 percent of whom died over a follow-up of five years [
         <a href="#rid4">
          4
         </a>
         ]. Patients with decreased strength had increased mortality risk even if muscle mass was normal (hazard ratio [HR] 1.98, 95% CI 1.01-3.87). Decreased muscle mass in the absence of decreased strength did not increase mortality in this study. This suggests that a functional assessment may provide prognostic information beyond that provided by assessment of muscle mass. (See
         <a class="local">
          'Screening'
         </a>
         above.)
        </p>
        <p>
         Decreased strength and endurance are important components of frailty, which is highly prevalent among older patients on dialysis [
         <a href="#rid91">
          91,92
         </a>
         ]. Among patients on dialysis, frailty has been associated with increased mortality [
         <a href="#rid92">
          92-98
         </a>
         ] and increased fractures [
         <a href="#rid99">
          99,100
         </a>
         ], as well as decreased quality of life [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1287847810">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110749.html" rel="external">
          "Society guideline links: Chronic kidney disease in adults"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/112932.html" rel="external">
          "Society guideline links: Dialysis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – Patients with advanced chronic kidney disease (CKD), particularly those on dialysis, often have significant muscle weakness and lack of endurance. This often results in a sedentary lifestyle that causes progressive deconditioning and increases morbidity and mortality among patients on dialysis. Exercise may reverse or mitigate effects of deconditioning and improve survival. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathophysiology
         </strong>
         – A decrease in striated muscle mitochondrial efficiency may occur in the early stage of CKD. Thereafter, progressive muscle impairment is caused by deconditioning. Erythropoietin, vitamin D, and androgen deficiencies all likely contribute to muscle weakness. (See
         <a class="local">
          'Pathophysiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Screening
         </strong>
         – We screen all patients on hemodialysis and selected patients with CKD not on hemodialysis for functional limitations. Screening for physical performance and self-reported functional limitation may identify patients at risk for further functional decline, disability, and increased mortality. Screening questions may be used, or physical performance may be objectively quantitated using functional tests. (See
         <a class="local">
          'Screening'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention
         </strong>
         – The prevention or treatment of deconditioning may delay or mitigate the progression of clinically significant muscle impairment. Our approach for all patients includes an exercise regimen plus optimal treatment of vitamin D deficiency, anemia, and nutrition and is defined above. Exercise in particular has numerous benefits including potential preservation of kidney function in patients with CKD not on dialysis and possible cardiovascular and survival benefits. (See
         <a class="local">
          'Prevention'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – Despite preventive therapies, some patients will have persistent and debilitating weakness. In addition to referring such patients to a physical therapist or an exercise physiologist, pharmacologic treatment options include
         <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">
          testosterone
         </a>
         and
         <a class="drug drug_general" data-topicid="10109" href="/z/d/drug information/10109.html" rel="external">
          carnitine supplementation
         </a>
         . However, there is no high-quality evidence to support their routine use. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – Decreased muscle strength is associated with increased mortality and contributes to increased falls, fracture risk, and frailty. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Clyne N, Esbjörnsson M, Jansson E, et al. Effects of renal failure on skeletal muscle. Nephron 1993; 63:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Painter P, Taylor J, Wolcott S, et al. Exercise capacity and muscle structure in kidney recipient and twin donor. Clin Transplant 2003; 17:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campistol JM. Uremic myopathy. Kidney Int 2002; 62:1901.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isoyama N, Qureshi AR, Avesani CM, et al. Comparative associations of muscle mass and muscle strength with mortality in dialysis patients. Clin J Am Soc Nephrol 2014; 9:1720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roshanravan B, Gamboa J, Wilund K. Exercise and CKD: Skeletal Muscle Dysfunction and Practical Application of Exercise to Prevent and Treat Physical Impairments in CKD. Am J Kidney Dis 2017; 69:837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peng H, Cao J, Yu R, et al. CKD Stimulates Muscle Protein Loss Via Rho-associated Protein Kinase 1 Activation. J Am Soc Nephrol 2016; 27:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang L, Wang XH, Wang H, et al. Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy. J Am Soc Nephrol 2010; 21:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roshanravan B, Kestenbaum B, Gamboa J, et al. CKD and Muscle Mitochondrial Energetics. Am J Kidney Dis 2016; 68:658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Echtay KS, Roussel D, St-Pierre J, et al. Superoxide activates mitochondrial uncoupling proteins. Nature 2002; 415:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tamaki M, Miyashita K, Wakino S, et al. Chronic kidney disease reduces muscle mitochondria and exercise endurance and its exacerbation by dietary protein through inactivation of pyruvate dehydrogenase. Kidney Int 2014; 85:1330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gamboa JL, Billings FT 4th, Bojanowski MT, et al. Mitochondrial dysfunction and oxidative stress in patients with chronic kidney disease. Physiol Rep 2016; 4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pagano AF, Brioche T, Arc-Chagnaud C, et al. Short-term disuse promotes fatty acid infiltration into skeletal muscle. J Cachexia Sarcopenia Muscle 2018; 9:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manfredini F, Lamberti N, Malagoni AM, et al. The role of deconditioning in the end-stage renal disease myopathy: physical exercise improves altered resting muscle oxygen consumption. Am J Nephrol 2015; 41:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johansen KL, Chertow GM, Ng AV, et al. Physical activity levels in patients on hemodialysis and healthy sedentary controls. Kidney Int 2000; 57:2564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Painter P. Physical functioning in end-stage renal disease patients: update 2005. Hemodial Int 2005; 9:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsieh RL, Lee WC, Chang CH. Maximal cardiovascular fitness and its correlates in ambulatory hemodialysis patients. Am J Kidney Dis 2006; 48:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heiwe S, Jacobson SH. Exercise training in adults with CKD: a systematic review and meta-analysis. Am J Kidney Dis 2014; 64:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barcellos FC, Santos IS, Umpierre D, et al. Effects of exercise in the whole spectrum of chronic kidney disease: a systematic review. Clin Kidney J 2015; 8:753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manfredini F, Mallamaci F, D'Arrigo G, et al. Exercise in Patients on Dialysis: A Multicenter, Randomized Clinical Trial. J Am Soc Nephrol 2017; 28:1259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guthrie M, Cardenas D, Eschbach JW, et al. Effects of erythropoietin on strength and functional status of patients on hemodialysis. Clin Nephrol 1993; 39:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davenport A. The effect of treatment with recombinant human erythropoietin on skeletal muscle function in patients with end-stage renal failure treated with regular hospital hemodialysis. Am J Kidney Dis 1993; 22:685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davenport A, King RF, Ironside JW, et al. The effect of treatment with recombinant human erythropoietin on the histological appearance and glycogen content of skeletal muscle in patients with chronic renal failure treated by regular hospital haemodialysis. Nephron 1993; 64:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson CH, Kemp GJ, Taylor DJ, et al. No effect of blood transfusion on muscle metabolism. Q J Med 1992; 85:897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teruel JL, Marcen R, Navarro-Antolin J, et al. Androgen versus erythropoietin for the treatment of anemia in hemodialyzed patients: a prospective study. J Am Soc Nephrol 1996; 7:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeGowin RL, Lavender AR, Forland M, et al. Erythropoiesis and erythropoietin in patients with chronic renal failure treated with hemodialysis and testosterone. Ann Intern Med 1970; 72:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cattran DC, Fenton SS, Wilson DR, et al. A controlled trial of nondrolone decanoate in the treatment of uremic anemia. Kidney Int 1977; 12:430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johansen KL, Mulligan K, Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA 1999; 281:1275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johansen KL, Painter PL, Sakkas GK, et al. Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: A randomized, controlled trial. J Am Soc Nephrol 2006; 17:2307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prabhala A, Garg R, Dandona P. Severe myopathy associated with vitamin D deficiency in western New York. Arch Intern Med 2000; 160:1199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mokta J, Balraj, Mokta K, et al. High Prevalence of Hypovitaminosis D in Patients Presenting with Proximal Muscle Weakness: A Sub-Himalayan Study. J Assoc Physicians India 2017; 65:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riche KD, Arnall J, Rieser K, et al. Impact of vitamin D status on statin-induced myopathy. J Clin Transl Endocrinol 2016; 6:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patten BM, Bilezikian JP, Mallette LE, et al. Neuromuscular disease in primary hyperparathyroidism. Ann Intern Med 1974; 80:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rollinson RD, Gilligan BS. Primary hyperparathyroidism presenting as a proximal myopathy. Aust N Z J Med 1977; 7:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneider C, Grimm T, Kress W, et al. Hyperparathyroidism in a patient with proximal myotonic myopathy (PROMM). Neuromuscul Disord 2000; 10:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delbridge LW, Marshman D, Reeve TS, et al. Neuromuscular symptoms in elderly patients with hyperparathyroidism: improvement with parathyroid surgery. Med J Aust 1988; 149:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mallette LE, Patten BM, Engel WK. Neuromuscular disease in secondary hyperparathyroidism. Ann Intern Med 1975; 82:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hajjar K, Hagenacker T. Neuromuscular Disorder as Initial Manifestation of Secondary Hyperparathyroidism - A Case Report. Eur J Transl Myol 2017; 27:6100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fagher B, Cederblad G, Eriksson M, et al. L-carnitine and haemodialysis: double blind study on muscle function and metabolism and peripheral nerve function. Scand J Clin Lab Invest 1985; 45:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siami G, Clinton ME, Mrak R, et al. Evaluation of the effect of intravenous L-carnitine therapy on function, structure and fatty acid metabolism of skeletal muscle in patients receiving chronic hemodialysis. Nephron 1991; 57:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaux EC, Taylor DJ, Altmann P, et al. Effects of carnitine supplementation on muscle metabolism by the use of magnetic resonance spectroscopy and near-infrared spectroscopy in end-stage renal disease. Nephron Clin Pract 2004; 97:c41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tawney KW, Dinwiddie L, Schrodt, et al. Changes in upper extremity function associated with vascular access creation. J Am Soc Nephrol 2001; 12:251A.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McElroy A, Silver M, Morrow L, Heafner BK. Proximal and distal muscle weakness in patients receiving hemodialysis for chronic uremia. Phys Ther 1970; 50:1467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rampersad C, Darcel J, Harasemiw O, et al. Change in Physical Activity and Function in Patients with Baseline Advanced Nondialysis CKD. Clin J Am Soc Nephrol 2021; 16:1805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johansen KL, Shubert T, Doyle J, et al. Muscle atrophy in patients receiving hemodialysis: effects on muscle strength, muscle quality, and physical function. Kidney Int 2003; 63:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leonard MB, Wehrli FW, Ziolkowski SL, et al. A multi-imaging modality study of bone density, bone structure and the muscle - bone unit in end-stage renal disease. Bone 2019; 127:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diesel W, Emms M, Knight BK, et al. Morphologic features of the myopathy associated with chronic renal failure. Am J Kidney Dis 1993; 22:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore GE, Parsons DB, Stray-Gundersen J, et al. Uremic myopathy limits aerobic capacity in hemodialysis patients. Am J Kidney Dis 1993; 22:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun DF, Chen Y, Rabkin R. Work-induced changes in skeletal muscle IGF-1 and myostatin gene expression in uremia. Kidney Int 2006; 70:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marcus RL, LaStayo PC, Ikizler TA, et al. Low Physical Function in Maintenance Hemodialysis Patients Is Independent of Muscle Mass and Comorbidity. J Ren Nutr 2015; 25:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Painter P, Marcus RL. Assessing physical function and physical activity in patients with CKD. Clin J Am Soc Nephrol 2013; 8:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roshanravan B, Robinson-Cohen C, Patel KV, et al. Association between physical performance and all-cause mortality in CKD. J Am Soc Nephrol 2013; 24:822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimura A, Paredes W, Pai R, et al. Step length and fall risk in adults with chronic kidney disease: a pilot study. BMC Nephrol 2022; 23:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johansen KL. Exercise in the end-stage renal disease population. J Am Soc Nephrol 2007; 18:1845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baker LA, March DS, Wilkinson TJ, et al. Clinical practice guideline exercise and lifestyle in chronic kidney disease. BMC Nephrol 2022; 23:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsuzawa R, Roshanravan B, Shimoda T, et al. Physical Activity Dose for Hemodialysis Patients: Where to Begin? Results from a Prospective Cohort Study. J Ren Nutr 2018; 28:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baggetta R, D'Arrigo G, Torino C, et al. Effect of a home based, low intensity, physical exercise program in older adults dialysis patients: a secondary analysis of the EXCITE trial. BMC Geriatr 2018; 18:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller ME, Rejeski WJ, Reboussin BA, et al. Physical activity, functional limitations, and disability in older adults. J Am Geriatr Soc 2000; 48:1264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fiatarone MA, O'Neill EF, Ryan ND, et al. Exercise training and nutritional supplementation for physical frailty in very elderly people. N Engl J Med 1994; 330:1769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McAuley E, Konopack JF, Morris KS, et al. Physical activity and functional limitations in older women: influence of self-efficacy. J Gerontol B Psychol Sci Soc Sci 2006; 61:P270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller BW, Cress CL, Johnson ME, et al. Exercise during hemodialysis decreases the use of antihypertensive medications. Am J Kidney Dis 2002; 39:828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossum K, Hancock E, Thompson S, et al. A Randomized Trial Examining the Impact of Timing of Intradialytic Cycling on Intradialytic Hypotension. Kidney Int Rep 2023; 8:1002.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Painter PL, Agarwal A, Drummond M. Physical Function and Physical Activity in Peritoneal Dialysis Patients. Perit Dial Int 2017; 37:598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarca B, Jesudason S, Bennett PN, et al. Exercise or physical activity-related adverse events in people receiving peritoneal dialysis: A systematic review. Perit Dial Int 2022; 42:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castaneda C, Gordon PL, Uhlin KL, et al. Resistance training to counteract the catabolism of a low-protein diet in patients with chronic renal insufficiency. A randomized, controlled trial. Ann Intern Med 2001; 135:965.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clyne N. The importance of exercise training in predialysis patients with chronic kidney disease. Clin Nephrol 2004; 61 Suppl 1:S10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyce ML, Robergs RA, Avasthi PS, et al. Exercise training by individuals with predialysis renal failure: cardiorespiratory endurance, hypertension, and renal function. Am J Kidney Dis 1997; 30:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Painter P, Carlson L, Carey S, et al. Physical functioning and health-related quality-of-life changes with exercise training in hemodialysis patients. Am J Kidney Dis 2000; 35:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo CY, Li L, Lo WK, et al. Benefits of exercise training in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1998; 32:1011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DePaul V, Moreland J, Eager T, Clase CM. The effectiveness of aerobic and muscle strength training in patients receiving hemodialysis and EPO: a randomized controlled trial. Am J Kidney Dis 2002; 40:1219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mustata S, Chan C, Lai V, Miller JA. Impact of an exercise program on arterial stiffness and insulin resistance in hemodialysis patients. J Am Soc Nephrol 2004; 15:2713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Vilsteren MC, de Greef MH, Huisman RM. The effects of a low-to-moderate intensity pre-conditioning exercise programme linked with exercise counselling for sedentary haemodialysis patients in The Netherlands: results of a randomized clinical trial. Nephrol Dial Transplant 2005; 20:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheema B, Abas H, Smith B, et al. Randomized controlled trial of intradialytic resistance training to target muscle wasting in ESRD: the Progressive Exercise for Anabolism in Kidney Disease (PEAK) study. Am J Kidney Dis 2007; 50:574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakkas GK, Sargeant AJ, Mercer TH, et al. Changes in muscle morphology in dialysis patients after 6 months of aerobic exercise training. Nephrol Dial Transplant 2003; 18:1854.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiner DE, Liu CK, Miao S, et al. Effect of Long-term Exercise Training on Physical Performance and Cardiorespiratory Function in Adults With CKD: A Randomized Controlled Trial. Am J Kidney Dis 2023; 81:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anding-Rost K, von Gersdorff G, von Korn P, et al. Exercise during Hemodialysis in Patients with Chronic Kidney Failure. NEJM Evid 2023; 2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manfredini F, D'arrigo G, Lamberti N, et al. The legacy effect of a home walking exercise programme in kidney failure patients on dialysis. Nephrol Dial Transplant 2022; 37:1974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenwood SA, Koufaki P, Mercer TH, et al. Effect of exercise training on estimated GFR, vascular health, and cardiorespiratory fitness in patients with CKD: a pilot randomized controlled trial. Am J Kidney Dis 2015; 65:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson-Cohen C, Littman AJ, Duncan GE, et al. Physical activity and change in estimated GFR among persons with CKD. J Am Soc Nephrol 2014; 25:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen IR, Wang SM, Liang CC, et al. Association of walking with survival and RRT among patients with CKD stages 3-5. Clin J Am Soc Nephrol 2014; 9:1183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kodama S, Saito K, Tanaka S, et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA 2009; 301:2024.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stack AG, Molony DA, Rives T, et al. Association of physical activity with mortality in the US dialysis population. Am J Kidney Dis 2005; 45:690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopes AA, Lantz B, Morgenstern H, et al. Associations of self-reported physical activity types and levels with quality of life, depression symptoms, and mortality in hemodialysis patients: the DOPPS. Clin J Am Soc Nephrol 2014; 9:1702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tabibi MA, Cheema B, Salimian N, et al. The effect of intradialytic exercise on dialysis patient survival: a randomized controlled trial. BMC Nephrol 2023; 24:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Battaglia Y, Amicone M, Mantovani A, et al. Home-based exercise in patients on maintenance dialysis: a systematic review and meta-analysis of randomized clinical trials. Nephrol Dial Transplant 2023; 38:2550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giannaki CD, Hadjigeorgiou GM, Karatzaferi C, et al. A single-blind randomized controlled trial to evaluate the effect of 6 months of progressive aerobic exercise training in patients with uraemic restless legs syndrome. Nephrol Dial Transplant 2013; 28:2834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hewitt NA, O'Connor AA, O'Shaughnessy DV, Elder GJ. Effects of cholecalciferol on functional, biochemical, vascular, and quality of life outcomes in hemodialysis patients. Clin J Am Soc Nephrol 2013; 8:1143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kopple JD. The rationale for the use of growth hormone or insulin-like growth factor I in adult patients with renal failure. Miner Electrolyte Metab 1992; 18:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johannsson G, Bengtsson BA, Ahlmén J. Double-blind, placebo-controlled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: anabolic effect and functional improvement. Am J Kidney Dis 1999; 33:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kopple JD, Cheung AK, Christiansen JS, et al. OPPORTUNITY&amp;trade;: a large-scale randomized clinical trial of growth hormone in hemodialysis patients. Nephrol Dial Transplant 2011; 26:4095.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johansen KL, Dalrymple LS, Delgado C, et al. Association between body composition and frailty among prevalent hemodialysis patients: a US Renal Data System special study. J Am Soc Nephrol 2014; 25:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McAdams-DeMarco MA, Law A, Salter ML, et al. Frailty as a novel predictor of mortality and hospitalization in individuals of all ages undergoing hemodialysis. J Am Geriatr Soc 2013; 61:896.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murray AM. Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden. Adv Chronic Kidney Dis 2008; 15:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li M, Tomlinson G, Naglie G, et al. Geriatric comorbidities, such as falls, confer an independent mortality risk to elderly dialysis patients. Nephrol Dial Transplant 2008; 23:1396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johansen KL, Dalrymple LS, Glidden D, et al. Association of Performance-Based and Self-Reported Function-Based Definitions of Frailty with Mortality among Patients Receiving Hemodialysis. Clin J Am Soc Nephrol 2016; 11:626.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johansen KL, Chertow GM, Jin C, Kutner NG. Significance of frailty among dialysis patients. J Am Soc Nephrol 2007; 18:2960.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee SY, Yang DH, Hwang E, et al. The Prevalence, Association, and Clinical Outcomes of Frailty in Maintenance Dialysis Patients. J Ren Nutr 2017; 27:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kallenberg MH, Kleinveld HA, Dekker FW, et al. Functional and Cognitive Impairment, Frailty, and Adverse Health Outcomes in Older Patients Reaching ESRD-A Systematic Review. Clin J Am Soc Nephrol 2016; 11:1624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McAdams-DeMarco MA, Suresh S, Law A, et al. Frailty and falls among adult patients undergoing chronic hemodialysis: a prospective cohort study. BMC Nephrol 2013; 14:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delgado C, Shieh S, Grimes B, et al. Association of Self-Reported Frailty with Falls and Fractures among Patients New to Dialysis. Am J Nephrol 2015; 42:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iyasere OU, Brown EA, Johansson L, et al. Quality of Life and Physical Function in Older Patients on Dialysis: A Comparison of Assisted Peritoneal Dialysis with Hemodialysis. Clin J Am Soc Nephrol 2016; 11:423.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7324 Version 36.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8459873" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Effects of renal failure on skeletal muscle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12780672" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Exercise capacity and muscle structure in kidney recipient and twin donor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12371997" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Uremic myopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25074839" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Comparative associations of muscle mass and muscle strength with mortality in dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28427790" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Exercise and CKD: Skeletal Muscle Dysfunction and Practical Application of Exercise to Prevent and Treat Physical Impairments in CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26054539" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : CKD Stimulates Muscle Protein Loss Via Rho-associated Protein Kinase 1 Activation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20056750" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27312460" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : CKD and Muscle Mitochondrial Energetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11780125" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Superoxide activates mitochondrial uncoupling proteins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24284514" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Chronic kidney disease reduces muscle mitochondria and exercise endurance and its exacerbation by dietary protein through inactivation of pyruvate dehydrogenase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27162261" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Mitochondrial dysfunction and oxidative stress in patients with chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29248005" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Short-term disuse promotes fatty acid infiltration into skeletal muscle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26067552" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The role of deconditioning in the end-stage renal disease myopathy: physical exercise improves altered resting muscle oxygen consumption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10844626" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Physical activity levels in patients on hemodialysis and healthy sedentary controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16191072" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Physical functioning in end-stage renal disease patients: update 2005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16797383" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Maximal cardiovascular fitness and its correlates in ambulatory hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24913219" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Exercise training in adults with CKD: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26613036" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Effects of exercise in the whole spectrum of chronic kidney disease: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27909047" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Exercise in Patients on Dialysis: A Multicenter, Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8448925" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Effects of erythropoietin on strength and functional status of patients on hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8238014" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The effect of treatment with recombinant human erythropoietin on skeletal muscle function in patients with end-stage renal failure treated with regular hospital hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8502342" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The effect of treatment with recombinant human erythropoietin on the histological appearance and glycogen content of skeletal muscle in patients with chronic renal failure treated by regular hospital haemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1484952" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : No effect of blood transfusion on muscle metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8808121" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Androgen versus erythropoietin for the treatment of anemia in hemodialyzed patients: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5448750" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Erythropoiesis and erythropoietin in patients with chronic renal failure treated with hemodialysis and testosterone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/609193" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : A controlled trial of nondrolone decanoate in the treatment of uremic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10208142" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16825332" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: A randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10789615" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Severe myopathy associated with vitamin D deficiency in western New York.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29322711" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : High Prevalence of Hypovitaminosis D in Patients Presenting with Proximal Muscle Weakness: A Sub-Himalayan Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29067242" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Impact of vitamin D status on statin-induced myopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4811792" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Neuromuscular disease in primary hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/270996" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Primary hyperparathyroidism presenting as a proximal myopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10996777" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Hyperparathyroidism in a patient with proximal myotonic myopathy (PROMM).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3393114" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Neuromuscular symptoms in elderly patients with hyperparathyroidism: improvement with parathyroid surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/47234" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Neuromuscular disease in secondary hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28458803" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Neuromuscular Disorder as Initial Manifestation of Secondary Hyperparathyroidism - A Case Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3890130" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : L-carnitine and haemodialysis: double blind study on muscle function and metabolism and peripheral nerve function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2017271" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Evaluation of the effect of intravenous L-carnitine therapy on function, structure and fatty acid metabolism of skeletal muscle in patients receiving chronic hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15218329" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Effects of carnitine supplementation on muscle metabolism by the use of magnetic resonance spectroscopy and near-infrared spectroscopy in end-stage renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Changes in upper extremity function associated with vascular access creation
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5472511" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Proximal and distal muscle weakness in patients receiving hemodialysis for chronic uremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34697092" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Change in Physical Activity and Function in Patients with Baseline Advanced Nondialysis CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12472795" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Muscle atrophy in patients receiving hemodialysis: effects on muscle strength, muscle quality, and physical function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31158505" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A multi-imaging modality study of bone density, bone structure and the muscle - bone unit in end-stage renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8238013" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Morphologic features of the myopathy associated with chronic renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8352254" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Uremic myopathy limits aerobic capacity in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16871256" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Work-induced changes in skeletal muscle IGF-1 and myostatin gene expression in uremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25836339" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Low Physical Function in Maintenance Hemodialysis Patients Is Independent of Muscle Mass and Comorbidity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23220421" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Assessing physical function and physical activity in patients with CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23599380" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Association between physical performance and all-cause mortality in CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35193493" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Step length and fall risk in adults with chronic kidney disease: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17442789" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Exercise in the end-stage renal disease population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35193515" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Clinical practice guideline exercise and lifestyle in chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28893466" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Physical Activity Dose for Hemodialysis Patients: Where to Begin? Results from a Prospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30342464" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Effect of a home based, low intensity, physical exercise program in older adults dialysis patients: a secondary analysis of the EXCITE trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11037014" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Physical activity, functional limitations, and disability in older adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8190152" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Exercise training and nutritional supplementation for physical frailty in very elderly people.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16960230" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Physical activity and functional limitations in older women: influence of self-efficacy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11920350" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Exercise during hemodialysis decreases the use of antihypertensive medications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37180520" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : A Randomized Trial Examining the Impact of Timing of Intradialytic Cycling on Intradialytic Hypotension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28970364" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Physical Function and Physical Activity in Peritoneal Dialysis Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15806502" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35485264" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Exercise or physical activity-related adverse events in people receiving peritoneal dialysis: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11730397" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Resistance training to counteract the catabolism of a low-protein diet in patients with chronic renal insufficiency. A randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15233242" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : The importance of exercise training in predialysis patients with chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9261028" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Exercise training by individuals with predialysis renal failure: cardiorespiratory endurance, hypertension, and renal function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10692275" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Physical functioning and health-related quality-of-life changes with exercise training in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9856517" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Benefits of exercise training in patients on continuous ambulatory peritoneal dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12460041" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : The effectiveness of aerobic and muscle strength training in patients receiving hemodialysis and EPO: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15466276" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Impact of an exercise program on arterial stiffness and insulin resistance in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15522901" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : The effects of a low-to-moderate intensity pre-conditioning exercise programme linked with exercise counselling for sedentary haemodialysis patients in The Netherlands: results of a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17900457" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Randomized controlled trial of intradialytic resistance training to target muscle wasting in ESRD: the Progressive Exercise for Anabolism in Kidney Disease (PEAK) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12937235" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Changes in muscle morphology in dialysis patients after 6 months of aerobic exercise training.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35944747" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Effect of Long-term Exercise Training on Physical Performance and Cardiorespiratory Function in Adults With CKD: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Exercise during Hemodialysis in Patients with Chronic Kidney Failure
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35641182" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : The legacy effect of a home walking exercise programme in kidney failure patients on dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25236582" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Effect of exercise training on estimated GFR, vascular health, and cardiorespiratory fitness in patients with CKD: a pilot randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24335971" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Physical activity and change in estimated GFR among persons with CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24832096" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Association of walking with survival and RRT among patients with CKD stages 3-5.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19454641" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15806472" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Association of physical activity with mortality in the US dialysis population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25278548" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Associations of self-reported physical activity types and levels with quality of life, depression symptoms, and mortality in hemodialysis patients: the DOPPS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37069527" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : The effect of intradialytic exercise on dialysis patient survival: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37202219" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Home-based exercise in patients on maintenance dialysis: a systematic review and meta-analysis of randomized clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23929523" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : A single-blind randomized controlled trial to evaluate the effect of 6 months of progressive aerobic exercise training in patients with uraemic restless legs syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23493381" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Effects of cholecalciferol on functional, biochemical, vascular, and quality of life outcomes in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1465073" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : The rationale for the use of growth hormone or insulin-like growth factor I in adult patients with renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10196013" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Double-blind, placebo-controlled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: anabolic effect and functional improvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21750157" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : OPPORTUNITY&amp;trade;: a large-scale randomized clinical trial of growth hormone in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24158987" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Association between body composition and frailty among prevalent hemodialysis patients: a US Renal Data System special study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23711111" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Frailty as a novel predictor of mortality and hospitalization in individuals of all ages undergoing hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18334236" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18057068" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Geriatric comorbidities, such as falls, confer an independent mortality risk to elderly dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26792529" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Association of Performance-Based and Self-Reported Function-Based Definitions of Frailty with Mortality among Patients Receiving Hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17942958" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Significance of frailty among dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28065454" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : The Prevalence, Association, and Clinical Outcomes of Frailty in Maintenance Dialysis Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27342598" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Functional and Cognitive Impairment, Frailty, and Adverse Health Outcomes in Older Patients Reaching ESRD-A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24131569" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Frailty and falls among adult patients undergoing chronic hemodialysis: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26381744" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Association of Self-Reported Frailty with Falls and Fractures among Patients New to Dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26712808" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Quality of Life and Physical Function in Older Patients on Dialysis: A Comparison of Assisted Peritoneal Dialysis with Hemodialysis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
